Therapeutic bronchoscopy for malignant central airway obstructions caused by non‐bronchogenic cancers: Results from the EpiGETIF registry

Abstract

AbstractBackground and ObjectiveLittle is known about malignant central airway obstruction (MCAO) complicating the metastatic spread of non‐bronchogenic solid cancers (NBC) and their bronchoscopic management. This study aimed to describe the epidemiology of this population and determine prognostic factors before therapeutic bronchoscopy (TB).MethodsIn this multicenter study using the EpiGETIF registry, we analysed patients treated with TB for MCAO caused by NBC between January 2019 and December 2022.ResultsFrom a database of 2389 patients, 436 patients (18%) with MCAO and NBC were identified. After excluding patients with direct local invasion, 214 patients (8.9%) were analysed. The main primaries involved were kidney (17.8%), colon (16.4%), sarcoma (15.4%), thyroid (8.9%) and head and neck (7.9%) cancers. Most patients (63.8%) had already received one or more lines of systemic treatment. Obstructions were purely intrinsic in 58.2%, extrinsic in 11.1% and mixed in 30.8%. Mechanical debulking was used in 73.4% of cases, combined with thermal techniques in 25.6% of cases. Airway stenting was required in 38.4% of patients. Median survival after TB was 11.2 months, influenced by histology (p = 0.002), performance status (p = 0.019), initial hypoxia (HR 1.45 [1.01–2.18]), prior oncologic treatment received (HR 1.82 [1.28–2.56], p < 0.001) and assessment of success at the end of the procedure (HR 0.66 [0.44–0.99], p < 0.001). Complications rate was 8.8%, mostly mild, with no procedure‐related mortality.ConclusionTB for MCAO caused by a NBC metastasis provides rapid improvement of symptoms and prolonged survival. Patients should be promptly referred by medical oncologists for bronchoscopic management based on the prognostic factors identified.